Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma.

ABSTRACT:

SUBMITTER: Dodero A 

PROVIDER: S-EPMC6756077 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature